FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3034380047> ?p ?o ?g. }

• W3034380047 abstract "Abstract Background This multi-center, retrospective study aimed to clarify retention rates and reasons for discontinuation of 7 biological disease-modifying antirheumatic drugs (bDMARDs) and tofacitinib (TOF), one of the janus kinase inhibitors, in bDMARDs-naïve and bDMARDs-switched patients with rheumatoid arthritis (RA). Methods This study assessed 3897 patients and 4415 treatment courses with bDMARDs and TOF from 2001 to 2019 (2737 bDMARDs-naïve courses and 1678 bDMARDs-switched courses [59.5% of switched courses were their second agent], female 82.3%, baseline age 57.4 years, disease duration 8.5 years; rheumatoid factor positivity 78.4%; Disease Activity Score in 28 joints using erythrocyte sedimentation rate 4.3; concomitant prednisolone [PSL] dose 6.1 mg/day [usage 42.4%], and methotrexate [MTX] dose 8.5 mg/week [usage 60.9%]). Treatment courses included abatacept (ABT; n = 663), adalimumab (ADA; n = 536), certolizumab pegol (CZP; n = 226), etanercept (ETN; n = 856), golimumab (GLM; n = 458), infliximab (IFX; n = 724), tocilizumab (TCZ; n = 851), and TOF ( n = 101/only bDMARDs-switched cases). Drug discontinuation reasons (categorized into lack of effectiveness, toxic adverse events, non-toxic reasons, or remission) and rates were estimated at 36 months using Gray’s test and statistically evaluated after adjusted by potential clinical confounders (age, sex, disease duration, concomitant PSL and MTX usage, starting date, and number of switched bDMARDs) using the Fine-Gray model. Results Cumulative incidence of drug discontinuation for each reason was as follows: lack of effectiveness in the bDMARDs-naïve group (from 13.7% [ABT] to 26.9% [CZP]; P < 0.001 between agents) and the bDMARDs-switched group (from 18.9% [TCZ] to 46.1% [CZP]; P < 0.001 between agents); toxic adverse events in the bDMARDs-naïve group (from 4.6% [ABT] to 11.2% [ETN]; P < 0.001 between agents) and the bDMARDs-switched group (from 5.0% [ETN] to 15.7% [TOF]; P = 0.004 between agents); and remission in the bDMARDs-naïve group (from 2.9% [ETN] to 10.0% [IFX]; P < 0.001 between agents) and the bDMARDs-switched group (from 1.1% [CZP] to 3.3% [GLM]; P = 0.9 between agents). Conclusions Remarkable differences were observed in drug retention of 7 bDMARDs and TOF between bDMARDs-naïve and bDMARDs-switched cases." @default.
• W3034380047 created "2020-06-19" @default.
• W3034380047 creator A5003548603 @default.
• W3034380047 creator A5018092891 @default.
• W3034380047 creator A5023433400 @default.
• W3034380047 creator A5026278665 @default.
• W3034380047 creator A5026633755 @default.
• W3034380047 creator A5033870789 @default.
• W3034380047 creator A5037662951 @default.
• W3034380047 creator A5039685784 @default.
• W3034380047 creator A5042491943 @default.
• W3034380047 creator A5043551691 @default.
• W3034380047 creator A5055194718 @default.
• W3034380047 creator A5062038717 @default.
• W3034380047 creator A5070689170 @default.
• W3034380047 creator A5074354992 @default.
• W3034380047 creator A5076008841 @default.
• W3034380047 creator A5078572977 @default.
• W3034380047 creator A5086225100 @default.
• W3034380047 date "2020-06-15" @default.
• W3034380047 modified "2023-10-17" @default.
• W3034380047 title "Drug retention of 7 biologics and tofacitinib in biologics-naïve and biologics-switched patients with rheumatoid arthritis: the ANSWER cohort study" @default.
• W3034380047 cites W1966439074 @default.
• W3034380047 cites W2016950635 @default.
• W3034380047 cites W2062027623 @default.
• W3034380047 cites W2079590652 @default.
• W3034380047 cites W2089883381 @default.
• W3034380047 cites W2096862304 @default.
• W3034380047 cites W2100569870 @default.
• W3034380047 cites W2102350540 @default.
• W3034380047 cites W2104669609 @default.
• W3034380047 cites W2106207910 @default.
• W3034380047 cites W2120393706 @default.
• W3034380047 cites W2121960517 @default.
• W3034380047 cites W2124045236 @default.
• W3034380047 cites W2124227426 @default.
• W3034380047 cites W2127696180 @default.
• W3034380047 cites W2133076005 @default.
• W3034380047 cites W2133668754 @default.
• W3034380047 cites W2139201413 @default.
• W3034380047 cites W2149223963 @default.
• W3034380047 cites W2152348310 @default.
• W3034380047 cites W2156617860 @default.
• W3034380047 cites W2211552606 @default.
• W3034380047 cites W2284636686 @default.
• W3034380047 cites W2554322291 @default.
• W3034380047 cites W2557395888 @default.
• W3034380047 cites W2563857970 @default.
• W3034380047 cites W2579871959 @default.
• W3034380047 cites W2782148001 @default.
• W3034380047 cites W2791681362 @default.
• W3034380047 cites W2885320772 @default.
• W3034380047 cites W2887186586 @default.
• W3034380047 cites W2895869275 @default.
• W3034380047 cites W2942970564 @default.
• W3034380047 cites W2944611922 @default.
• W3034380047 cites W2980782789 @default.
• W3034380047 cites W3012317449 @default.
• W3034380047 cites W4236700223 @default.
• W3034380047 cites W4241931138 @default.
• W3034380047 cites W4243348309 @default.
• W3034380047 doi "https://doi.org/10.1186/s13075-020-02232-w" @default.
• W3034380047 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7296929" @default.
• W3034380047 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32539813" @default.
• W3034380047 hasPublicationYear "2020" @default.
• W3034380047 type Work @default.
• W3034380047 sameAs 3034380047 @default.
• W3034380047 citedByCount "23" @default.
• W3034380047 countsByYear W30343800472021 @default.
• W3034380047 countsByYear W30343800472022 @default.
• W3034380047 countsByYear W30343800472023 @default.
• W3034380047 crossrefType "journal-article" @default.
• W3034380047 hasAuthorship W3034380047A5003548603 @default.
• W3034380047 hasAuthorship W3034380047A5018092891 @default.
• W3034380047 hasAuthorship W3034380047A5023433400 @default.
• W3034380047 hasAuthorship W3034380047A5026278665 @default.
• W3034380047 hasAuthorship W3034380047A5026633755 @default.
• W3034380047 hasAuthorship W3034380047A5033870789 @default.
• W3034380047 hasAuthorship W3034380047A5037662951 @default.
• W3034380047 hasAuthorship W3034380047A5039685784 @default.
• W3034380047 hasAuthorship W3034380047A5042491943 @default.
• W3034380047 hasAuthorship W3034380047A5043551691 @default.
• W3034380047 hasAuthorship W3034380047A5055194718 @default.
• W3034380047 hasAuthorship W3034380047A5062038717 @default.
• W3034380047 hasAuthorship W3034380047A5070689170 @default.
• W3034380047 hasAuthorship W3034380047A5074354992 @default.
• W3034380047 hasAuthorship W3034380047A5076008841 @default.
• W3034380047 hasAuthorship W3034380047A5078572977 @default.
• W3034380047 hasAuthorship W3034380047A5086225100 @default.
• W3034380047 hasBestOaLocation W30343800471 @default.
• W3034380047 hasConcept C126322002 @default.
• W3034380047 hasConcept C197934379 @default.
• W3034380047 hasConcept C2776215756 @default.
• W3034380047 hasConcept C2776715498 @default.
• W3034380047 hasConcept C2777138892 @default.
• W3034380047 hasConcept C2777178219 @default.
• W3034380047 hasConcept C2777226972 @default.
• W3034380047 hasConcept C2777575956 @default.
• W3034380047 hasConcept C2778715236 @default.
• W3034380047 hasConcept C2778886723 @default.

• next